San Diego, CA, United States of America

Feng Zhang

This inventor holds 12 USPTO granted patents and 1 published patent application and 5 EPO patents. Top assignee: Senomyx, Inc.. Active years: 2011-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Feng Zhang. Retrieved from https://idiyas.com/inventor/feng-zhang-lthdof9m

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 12 

% Patents Active = 100.0

 

Average Co-Inventor Count = 9.8

ph-index = 7

Forward Citations = 260(Granted Patents)


Company Filing History:


Years Active: 2011-2018

Loading Chart...
Loading Chart...
12 patents (USPTO):Explore Patents

Title: The Innovative Journey of Inventor Feng Zhang

Introduction: Feng Zhang is a renowned inventor based in San Diego, CA, known for his groundbreaking contributions to the field of biotechnology and genetic engineering.

Latest Patents: Feng Zhang holds several patents related to CRISPR-Cas9 gene editing technology, including patents for novel applications in agriculture, medicine, and biotechnology.

Career Highlights: With a background in bioengineering and molecular biology, Feng Zhang has made significant strides in developing CRISPR-based tools for precise genome editing, earning him recognition as one of the leading innovators in the field.

Collaborations: Feng Zhang has collaborated with top research institutions, biotech companies, and universities worldwide to further explore the potential of CRISPR technology in various industries, fostering a culture of innovation and collaboration.

Conclusion: Feng Zhang's pioneering work in the field of genetic engineering continues to inspire new advancements and applications, shaping the future of biotechnology and precision medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…